The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Not this decade, experts say. Thanks largely to loopholes in ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...